Great study on using HCG, HMG, and FSH to treat azoospermia due to male hypogonadotropic hypogonadism: A total of 137 MHH patients (congenital in 79 patients, acquired in 42 patients and adult‐onset in 16 patients) were collected from 16 clinical centers in Japan. A total of 33 of these patients did not meet the study inclusion criteria and were excluded. Three treatments were investigated in the present study: (i) hCG monotherapy; (ii) hCG + hMG combination therapy; and (iii) hCG + rhFSH combination therapy. If spermatogenesis was not induced after treatment with hCG monotherapy or hCG + hMG combination therapy, hCG + rhFSH was used as a second‐line treatment.
Investigation of treatment for azoospermia due to male hypogonadotropic hypogonadism in Japan
Investigation of treatment for azoospermia due to male hypogonadotropic hypogonadism in Japan